Episode 51: Lipoprotein(a): Genetic Risk, Seed Oils & 5 Steps to Protect Your Heart

Show Notes

Lipoprotein(a), or LP(a), is perhaps the most misunderstood and under-tested particle in cardiology. Unlike regular LDL, LP(a) levels are nearly 100% determined by your genetics and cannot be modified by traditional diet or exercise. And yet roughly one in four adults globally carry levels high enough to double their lifetime risk of heart attack and stroke, and almost none of them know it.

In this Tuesday deep dive, Dr. Ravi Kumar picks up where Monday’s sneak preview left off and walks through the full story of LP(a). He starts with the basics: LP(a) is a modified LDL particle with an extra protein attached, the apo(a) protein, that almost perfectly mimics plasminogen, your body’s clot-dissolving protein. That structural mimicry gives LP(a) two unique behaviors. It slows clot breakdown and helps wounds seal faster, and it acts as a magnet for oxidized fats in the bloodstream.

The number itself is locked in by your DNA, 70 to 90% genetic, and diet and exercise basically do not move it. Black and African individuals tend to run up to three times higher than European populations. South Asian populations also trend higher. Women run 5 to 10% higher than men, and levels can climb further at menopause. If your LP(a) is high, your first-degree relatives, your kids and your siblings, have a real chance of carrying it too, which is why family screening is one of the most practical things you can do with this information.

Then Dr. Kumar reframes the whole problem. If LP(a) were purely harmful, natural selection would have wiped it out a long time ago. It survived because it was useful. In the ancestral world, high LP(a) meant better wound sealing, fewer fatal childbirth hemorrhages, and faster recovery from animal attacks and battlefield injuries. LP(a) rushes to the site of vascular injury like an emergency supply truck, stabilizes clots, delivers cholesterol and repair materials, and helps coordinate the immune response. It is found only in old world primates and humans, preserved across tens of millions of years of evolution. It is not a mistake.

The problem is what we call an evolutionary mismatch. In the modern world, the injury never stops. Chronic hypertension shears the inside of your blood vessels. Metabolic disease and insulin resistance glycate and inflame those same walls. Smoking oxidizes the endothelium with every puff. LP(a) keeps showing up to repair, keeps depositing cholesterol, and the macrophages that should be cleaning up get overwhelmed. Atherosclerosis in this framework is not a disease of too much cholesterol; it is a disease of overzealous, chronically activated endothelial repair in an environment of unrelenting vascular injury.

And then there is the second switch. LP(a) is the dominant carrier of oxidized phospholipids in the bloodstream, and those oxidized lipids, mostly from industrial seed oils like corn, soybean, canola, sunflower, and cottonseed, are the fuel that initiates foam cell formation and arterial plaque. The Tokelauan islanders and the Masai of East Africa, two populations historically eating very high saturated fat diets, illustrate the point: their fats do not oxidize readily, and historically their rates of atherosclerosis were remarkably low even in the context of heavy smoking.

The episode closes with the 5-step framework Dr. Kumar uses personally to manage his own elevated LP(a): get seed oils out of the diet and cook with stable fats only, control blood pressure under 120 over 80, dial in metabolic health, stay physically active, and do not smoke. He also covers low-dose aspirin (worth a conversation with your physician based on Women’s Health Study data), aggressive LDL lowering as a fallback, and the pharmacological landscape: lipoprotein apheresis, PCSK9 inhibitors as a 20 to 25% secondary effect, and the new class of siRNA therapies in late-stage trials that can knock LP(a) down by 70 to 90% with dosing every three to six months.

In this episode, you will discover:

What LP(a) actually is: A modified LDL particle with the apo(a) protein attached, structurally almost identical to plasminogen, your body’s clot-dissolving protein
The naming confusion that trips people up: Why apo A (capital A, apolipoprotein A1, on HDL) is completely different from apo(a) (little a, on LP(a)), even though doctors and patients often confuse them
Why LP(a) is hiding from your doctor: LP(a) is not on the standard lipid panel and you have to ask for it specifically, even though 20 to 25% of the global population has levels high enough to matter
The two units and the threshold: Why nanomoles per liter is the more accurate measurement, and why 125 nmol/L is generally considered the high-risk threshold
Why your DNA controls it: LP(a) levels are 70 to 90% determined by a single gene, the LPA gene, stable from age five for the rest of your life, regardless of diet or exercise
The ancestry pattern: Why Black and African populations run up to three times higher, why South Asian populations trend higher, and why East Asian populations tend to be lower
The gender pattern: Why women run 5 to 10% higher than men and why menopause makes it worse
The evolutionary superpower: How LP(a) crowds out plasminogen at injury sites, stabilizes clots, and delivers more than 35 accessory proteins including coagulation factors and immune mediators to help sealed wounds heal
Why LP(a) only exists in old world primates and humans: Preserved across tens of millions of years of evolution, which tells you something important about what it does
The evolutionary mismatch: Why chronic hypertension, metabolic disease, and smoking turn an emergency repair system into an always-on plaque-building system
Atherosclerosis reframed: A disease of chronically activated endothelial repair under unrelenting vascular injury, not a disease of too much cholesterol
The seed oil connection: Why loading LP(a) particles with oxidized fats from corn, soybean, canola, sunflower, and cottonseed oils is what turns the repair system into plaque initiation
The Tokelauan and Masai paradox: Why two populations eating very high saturated fat diets (and in the Tokelauans, smoking heavily) historically had remarkably low rates of atherosclerosis
The clinical risk numbers: Why elevated LP(a) above 125 nmol/L is associated with a 2 to 3 times increased risk of heart attack, plus independent associations with ischemic stroke, peripheral artery disease, and calcific aortic stenosis
The Mendelian randomization evidence: Why the relationship between LP(a) and cardiovascular disease is causal, not just correlational
The 5-step framework: Eliminate seed oils, control blood pressure, fix metabolic health, stay active, and do not smoke
The aspirin question: Why a post hoc analysis of the Women’s Health Study suggested low-dose aspirin may meaningfully benefit people with the LP(a) genetic variants
The pharmacological pipeline: Lipoprotein apheresis (60 to 90% acute reduction every two weeks at specialty centers), PCSK9 inhibitors (20 to 25% secondary effect), and the new siRNA therapies in late-stage trials (70 to 90% reduction every three to six months)

Key Takeaways

LP(a) is a modified LDL particle that carries cholesterol, mimics the clot-dissolving protein plasminogen, and binds oxidized fats; in the ancestral world that combination was protective
The number is locked in by your DNA at 70 to 90%, so the goal is not to move the number but to remove the two conditions that allow LP(a) to cause harm
The two conditions are chronic endothelial injury (hypertension, metabolic disease, smoking) and oxidized fats loaded onto LP(a) particles (mostly from industrial seed oils)
Atherosclerosis is best understood as overzealous, chronically activated endothelial repair in an environment of unrelenting injury, not simply a disease of too much cholesterol
High LP(a) is a heritable trait; if yours is elevated, get your first-degree relatives checked so they can act on the same framework
The 5-step protocol: eliminate seed oils, keep blood pressure under 120 over 80, dial in metabolic health, exercise regularly, do not smoke
siRNA therapies in late-stage trials are knocking LP(a) down by 70 to 90% with quarterly to semiannual dosing, but lifestyle changes are available today, have no side effects, and address the root cause

Episode Resources

Dr. Ravi Kumar on LinkedIn
Dr. Ravi Kumar’s Website

Transcript

[00:00 –> 00:35] Dr. Ravi Kumar: On this episode of the Dr Kumar Discovery, what actually is lipoprotein little a, and why should you care about it? Somewhere between 20 to 25% of the global population has levels high enough to matter, and most of them have no idea. If you have high LP little a, your first degree relatives, your kids, your siblings, they have a definite chance of having it too. If LP little a was purely harmful, evolution would have wiped it out of the gene pool a long time ago. If your result is in that range or higher, this episode is exactly for you.

[00:35 –> 01:05] Dr. Ravi Kumar: My name is Dr. Ravi Kumar. I’m a neurosurgeon in search of the causes of human illness and the solutions that help us heal and thrive. I want you to join me on a journey of discovery as I turn over every stone in search of the roots of disease and the mysteries of our resilience. The human body is a mysterious and miraculous machine with an amazing ability to self heal. Let us question everything and discover our true potentials. Welcome to the Dr Kumar Discovery.

[01:05 –> 03:01] Dr. Ravi Kumar: Welcome to the Dr Kumar Discovery. My name is Dr. Ravi Kumar. I’m a board certified neurosurgeon and assistant professor at UNC. On today’s episode, we’re gonna be talking about a lipoprotein called LP little a, or lipoprotein little a. It’s a lipoprotein that’s heavily implicated in cardiovascular disease. And it’s one of the only biomarkers in cardiology that is essentially not modifiable by diet or lifestyle. It’s almost completely determined by your genetics. And the prevailing message out there is that if you have elevated lipoprotein little a or LP little a like I do, this is basically a genetic bad hand. You’re at much higher risk for cardiovascular disease, and there’s not a whole lot you can do about it. Well, based on the evidence, based on the literature, based on biology, based on common sense, and based on the actual mechanisms of how atherosclerotic disease works, I don’t believe that’s the case. And I’m going to explain to you today why having elevated lipoprotein little a is not a death sentence. In fact, it’s a superpower as long as you know how to modify your life so that it never becomes a bad actor. So before we get into all that, I want to give you a quick note, and this is something I do at the beginning of every show, and that’s to tell you that this show is completely separate from my role as assistant professor at UNC. Everything I do here is for informational purposes only. I’m not your doctor, but I am giving you solid, evidence based information that you can use to empower yourself with knowledge and then work with your own healthcare provider to make the best decisions for your own health. Okay, let’s get into it.

[03:02 –> 04:50] Dr. Ravi Kumar: And let’s start with the basics. What actually is lipoprotein little a, and why should you care about it? So most of us are familiar with LDL, the so called bad cholesterol. Your standard lipid panel gives you LDL, HDL, total cholesterol, and triglycerides. But lipoprotein little a, the little lipoprotein that we’re talking about in this episode, is not on that panel. It has to be specifically ordered, and most people, including a lot of physicians, have never even thought to check for it. So right there, we have a problem because somewhere between 20 to 25% of the global population has levels high enough to matter, and most of them have no idea. So throughout this podcast, sometimes I’m going to say lipoprotein little a, and sometimes I’m going to say LP little a. They’re the same thing. They’re talking about this atherogenic particle that is the topic of this whole episode. So just keep that in mind. Now before I explain what LP little a or lipoprotein little a is, let me clear up a naming confusion that trips up people all the time because there are two completely different proteins with very similar names in the lipid system. There’s another lipoprotein called apo A, with a capital A, which is short for apolipoprotein A1. That’s the primary protein on HDL molecules, your quote unquote good cholesterol. When your doctor talks about apo A, they’re talking about your HDL system, which delivers cholesterol away from your cells and back to your liver. But then there’s another protein called apo little a, which is the unique protein that lives exclusively on lipoprotein little a particles. Different gene, different function, different story entirely, so don’t confuse these two. Okay.

[04:51 –> 05:59] Dr. Ravi Kumar: So what is LP little a or lipoprotein little a? Think of it as a modified LDL particle. Regular LDL carries cholesterol through your bloodstream to be delivered to cells that need it for repair and maintenance. LP little a does the same thing, but it has an extra protein attached to it, that apo little a protein we talked about. And this gives LP little a properties that LDL just doesn’t have. One of those properties comes from the fact that the apo little a protein is almost structurally identical to a protein called plasminogen. Now plasminogen is your body’s clot dissolving protein. When you activate it, it becomes plasmin, and plasmin breaks down fibrin clots. It’s critical to your body’s ability to dissolve clots after they form. Now the fact that apo little a looks almost exactly like plasminogen is not a coincidence. That is by design, and that helped us survive in the harsh world before modern society. And it’s also part of the source of LP little a’s cardiovascular risk as we’ll get into in a minute.

[06:00 –> 07:39] Dr. Ravi Kumar: The second important property that causes cardiovascular disease in association with LP little a is that lipoprotein little a is the dominant carrier of something called oxidized phospholipids in your bloodstream. And this is actually more important than most people realize. Regular LDL carries some oxidized fats, but LP little a particles have a structural affinity for them, almost like a magnet. So when you have oxidized lipids floating around in your bloodstream, a disproportionate amount of them end up getting loaded onto your LP little a particles. And those oxidized lipids are one of the main reasons LP little a becomes dangerous in the modern environment, which we’ll also come back to in a second. Now let’s talk about where LP little a comes from. And this is where it gets both fascinating and for a lot of people, a little frustrating. Your LP little a level is somewhere between 70 to 90% determined by a single gene called the LPA gene. Your entire LP little a is locked in at birth. Diet doesn’t move it meaningfully. Exercise doesn’t move it either. It’s essentially stable and at the same level from age five and for the rest of your life. And there’s also an ethnic and hereditary dimension to this. Black and African individuals tend to have slightly higher LP little a levels on average, up to about three times higher than European populations. And people with South Asian ancestry, like me, also trend higher. East Asian populations tend to be lower. These differences are almost entirely genetic, driven by differences in LPA allele frequency across these populations.

[07:40 –> 09:08] Dr. Ravi Kumar: Also, women tend to run about 5 to 10% higher than men, and levels can increase further at menopause. And because of this heritability, if you have high LP, your first degree relatives, your kids, your siblings, they have a definite chance of having it too. Getting your family checked is one of the most practical things you can do with this information because it will allow you to modify your risk factors accordingly, and we’ll talk about how to do that in a bit. Now on the measurement side, I’m not going to spend a lot of time here, but you should definitely get it checked. And when you do, there are two units that are sometimes used, milligrams per deciliter and nanomoles per liter. And they’re not interchangeable. Nanomoles per liter is the more accurate measurement because it counts actual particles regardless of their size. The high risk threshold is generally considered to be 125 nanomoles per liter or above, which is roughly 50 milligrams per deciliter. If your result is in that range or higher, this episode is exactly for you. And again, you have to ask for this test specifically. It’s not on the standard lipid panel. The National Lipid Association and the European guidelines now both recommend that every adult get this checked at least once in their life. But most primary care visits still don’t include it, so you have to ask for it.

[09:08 –> 09:32] Dr. Ravi Kumar: Hey guys. I created this podcast because there’s too much confusion out there. There’s too much noise, too many conflicting messages about our health. My goal was simple when I made this podcast. I wanna cut through all of that and give you information that you can actually use. If that resonates with you, here’s how you can help. Leave a rating and a review on Apple Podcasts. Share an episode that resonated with you with someone else that you care about, and that’s how the show grows. That’s how we reach more people who are searching for answers. Thanks for being a part of this, and I appreciate your help.

[09:33 –> 12:25] Dr. Ravi Kumar: Okay. Here’s where I wanna spend some real time, because this is the piece that changes everything. If LP little a was purely harmful, evolution would have wiped it out of the gene pool a long time ago. Natural selection is ruthless about anything that consistently kills people before they reproduce. But LP little a not only survived, it is present in a substantial fraction of the human population. That tells us something important. It was useful. Very useful, actually. To understand why, remember what I said earlier. The apo a protein in LP little a is structurally almost identical to plasminogen, your clot dissolving protein. Now think about what that means functionally. When you get injured and bleeding starts, your body immediately begins forming a clot at the wound site. A protein in your blood called fibrin forms a mesh, and then platelets pile into it to create a clump that stops the bleeding. But there’s a competing system started at the same time, and it’s the fibrinolytic system, which is constantly working to dissolve those same clots. That system is driven by plasminogen being activated into plasmin, which actively busts up clots. Now here’s where LP little a comes in. Because the apo a protein looks like plasminogen, it competes for the same binding sites on fibrin and on the vessel walls that activate plasminogen. It shows up at the injury site and essentially crowds out plasminogen, reducing how much plasmin gets generated from plasminogen. Less plasmin means less clot dissolution. The clot holds longer, and the wound stays sealed. In the ancestral world, high LP little a meant better wound sealing, meaning less fatal childbirth hemorrhages, animal attacks, battlefield injuries. You bled less with any of these, and you survived if you had higher LP levels. On top of that, LP rushes to the site of vascular injury and delivers cholesterol and other lipid building materials directly to the injured tissues. Think of it as an emergency supply truck. Injury happens, LP little a shows up, stabilizes the clot, delivers repair materials, and helps coordinate the immune response. It carries more than 35 accessory proteins, including coagulation factors and immune mediators.

[12:25 –> 13:37] Dr. Ravi Kumar: It is a remarkably sophisticated repair system. And here’s another cool thing to know. LP little a is found only in old world primates and humans. It evolved specifically in our branch of the evolutionary tree. Given that it’s been preserved across tens of millions of years of primate evolution, the idea that this was just a mistake, just an accident that causes heart disease, doesn’t hold up biologically or to common sense. So why does it become a problem today then? Well, this is something we call an evolutionary mismatch. In the ancestral world, LP little a was a godsend. When you had an injury, LP little a rushed in, the clot was stabilized, the wound healed, and then the repair system turned off naturally. It was a response to an emergency event, and it saved lives. But in the modern world, this type of injury never stops. Chronic hypertension creates constant mechanical shear stress on the inner lining of your blood vessels. Metabolic disease and insulin resistance creates glycation and chronic inflammation in those same vessel walls. Smoking directly oxidizes the endothelium with every puff. And when LP little a shows up continuously to constantly injured vessel walls, it’s not just doing emergency repair anymore. It’s accumulating. It’s depositing cholesterol for repair and healing in these vessels over and over again. And the macrophages that were supposed to clean things up become overwhelmed, and atherosclerosis begins.

[13:38 –> 15:47] Dr. Ravi Kumar: Atherosclerosis in this framework is not a disease of too much cholesterol. It’s a disease of overzealous, chronically activated endothelial repair in an environment of unrelenting vascular injury. Now add in another layer to that. I mentioned earlier that LP little a is the primary carrier of oxidized phospholipids in the bloodstream. And those oxidized lipids matter enormously because they are the actual trigger for atherosclerosis. Here’s how that works. When LP little a particles are loaded with oxidized fats and they accumulate in the vessel wall from constant delivery from the constant injury that’s calling LP little a in, the macrophages that come in to clean up the damage can’t process these oxidized lipids normally. They can’t use them. They can’t deliver them. They can’t get rid of them. And so they just keep engulfing them, and they become these big bloated cells called foam cells. And foam cells, which are these bloated macrophages, they don’t leave the vessel wall. They die in place and form the core of plaque. Now where do these oxidized lipids come from? Well, it’s largely from industrially processed seed oils. Corn oil, soybean oil, canola oil, sunflower oil. These oils are rich in polyunsaturated fats like linoleic acid. And polyunsaturated fats oxidize readily, both during cooking and inside your body. When you eat these oils regularly, you’re loading your LP little a particles with the exact fuel that initiates arterial plaques. There’s actually a fascinating natural experiment that I love talking about. The Tokelauan islanders and the Masai of East Africa are two populations that have historically eaten very high fat diets, predominantly saturated fat. And the Tokelauans smoke like chimneys. By conventional cardiovascular medicine logic, they should have sky high rates of heart disease. But historically, their rates of atherosclerosis have been remarkably low.

[15:48 –> 20:48] Dr. Ravi Kumar: Why? Because saturated fats are chemically stable. They don’t oxidize readily. So even in the context of some vascular injury from smoking, LP little a particles and LDL particles in these populations are not loaded with oxidized pro inflammatory fuel. Instead, they carry nonoxidizable saturated fats. So in their situations, the mechanism for plaque initiation is simply not activated. So let me tie this all together before we move on. High LP little a means you have a more aggressive wound healing system. That system responds to signals of vascular injury by rushing to the scene, forming more stable clots, and depositing repair materials. If you’re constantly injuring your endothelium through hypertension, metabolic disease, or smoking, your repair system is in overdrive all the time. And if you’re simultaneously loading your LP little a molecules with oxidizable fats from seed oils, every batch of repair materials that it delivers is laced with figurative dynamite. That is the combination that causes problems. LP by itself is not the problem. Okay. So that being said, if you look at LP in isolation in the literature, meaning you ignore these other potentiating factors, clinical data shows real risks with elevated levels. Elevated LP above the 125 nanomole per liter threshold is associated with roughly a 2 to 3 times increased risk of heart attacks compared to people with low levels. And it’s independently associated with ischemic stroke, peripheral artery disease, and a condition called calcific aortic stenosis, which is hardening of the aortic valve. And the clinical evidence is causal too, not just correlational. Researchers ran Mendelian randomization studies, which use human genetics essentially as a natural experiment, and confirmed that LP is a driving factor in cardiovascular disease. But here’s what those statistics don’t tell you. Many people with very high LP levels never have a cardiovascular event. And the reason I believe is exactly what we just discussed. The risk is not in the number on your lab report. The risk is in what you do with the rest of your biology. LP little a combined with uncontrolled hypertension, diabetes or smoking, and a diet full of seed oils is a very different situation than LP little a in a metabolically healthy person who eats clean and takes care of their vascular system.

[20:49 –> 22:30] Dr. Ravi Kumar: The best way to look at this is that your LP little a number raises your probability of cardiovascular event if it’s high under certain circumstances, but it does not determine your destiny. Okay. So let’s talk about what you can do if you have a high LP little a level. And I want to reiterate something here. Your LP level itself is not something you can move with lifestyle. I know that that’s not what people want to hear, but it’s true. The number is in your DNA, and diet and exercise are not going to meaningfully change it. But based on everything we just talked about, moving a number is not the actual goal. The goal is removing the two conditions that allow LP little a to cause harm. You do this by one, stop chronically injuring your endothelium, and two, stop loading your LP little a particles with oxidizable fats. Do those two things, and having a high LP little a level is essentially a non issue. So let’s talk about how to do this practically. Number one, and I put this first, is because I think it’s the most underrated intervention available to people today, is to get seed oils out of your diet. Corn oil, soybean oil, canola oil, sunflower oil, cottonseed oil, these are the primary sources of oxidizable polyunsaturated fats in the modern diet. They’re in almost every processed food, most restaurant food, and most packaged snacks. When you reduce these oils in your diet, you reduce the oxidized lipid load that your LP little a particles are carrying, and you reduce the inflammation that initiates foam cell formation and atherosclerosis in your arteries. Replace seed oils with stable fats that don’t oxidize. Olive oil, avocado oil, butter, tallow, coconut oil. Cook them at appropriate temperatures below their smoke points, and realize that this is not about avoiding fat. It’s about choosing fats that don’t oxidize. Saturated fats and monounsaturated fats are chemically stable. That’s the key distinction. So if you wanna learn more about seed oils and how they affect our health, I did a whole episode on this topic. And if you listen to it, you’ll be very well informed.

[22:30 –> 24:00] Dr. Ravi Kumar: Okay. Number two. Control your blood pressure. Hypertension is continuous mechanical injury to your endothelium. Every beat of your heart under elevated pressure is shearing the inner lining of your blood vessels if you’re not exercising. And this creates tiny injury signals constantly that call LP little a to the scene. Getting your blood pressure under 120 over 80 resting is not just a number on a chart. For someone with high LP little a levels, it directly reduces the frequency and the intensity of the repair signals that drive plaque formation. Number three is metabolic health. Insulin resistance and chronically elevated blood glucose create glycation on your vessel walls and amplify vascular inflammation. This is another continuous injury signal. If your fasting insulin is high, if your blood sugar is poorly controlled, if your triglyceride to HDL ratio is out of range, you’re creating the exact kind of chronic endothelial stress that activates LP little a repeatedly. Getting your metabolic health dialed in is protective at the root cause of vascular health. And number four. Stay physically active. Now I want to be clear. Exercise does not lower your LP little a number. Studies have looked at this, and the effect is essentially negligible. But regular exercise powerfully reduces every other factor that amplifies LP little a risk. It improves insulin sensitivity. It lowers blood pressure. It reduces triglycerides. It improves endothelial function and nitric oxide production, which is the signaling molecule that keeps your vessel walls healthy and pliable. Think of exercise not as a way to move your LP little a number, but as a way to build a healthier vascular environment. And number five, don’t smoke. This probably goes without saying, but in the context of LP little a, it’s worth being explicit. Smoking is one of the most direct and aggressive forms of endothelial injury that there is. For someone with high LP little a levels, it is essentially pouring gasoline on the repair system.

[24:00 –> 24:19] Dr. Ravi Kumar: So the framework is simple. Stop injuring your endothelium and stop filling your lipoproteins with oxidizable fats. And LP goes from harmful to evolutionarily appropriate. A couple of other things worth a quick mention. There is some evidence, mostly from a post hoc analysis of the Women’s Health Study, that low dose aspirin may provide meaningful benefit specifically in those who carry the genetic variants that lead to high LP little a levels. The idea is that aspirin’s antiplatelet effects might counteract some of LP little a’s tendency to promote robust clot formation. This is worth discussing with your physician, particularly if you have other cardiovascular risk factors and a low bleeding risk. And on the question of whether people with high LP little a levels should aggressively lower their overall cholesterol burden, I’ll say this. If for some reason you cannot fully control other factors, if you’re dealing with blood pressure issues that are hard to manage or you have a situation where you genuinely can’t eliminate all the dietary oxidative stress, then yes. Reducing your overall atherogenic particle burden by lowering LDL aggressively through medication does make sense as a way to reduce your total inflammatory load on your vessel walls. That is a legitimate strategy in that context, but it should not replace the foundational steps that we mentioned.

[24:20 –> 26:38] Dr. Ravi Kumar: Now let me spend a couple minutes on the pharmacological side, because I think there are some things worth paying attention to here. Currently, there is no FDA approved drug that specifically targets LP little a reduction in a way that has been proven to reduce cardiovascular events. There is lipoprotein apheresis, which is a blood filtration procedure that can acutely reduce LP by 60 to 90%. It’s the most effective thing we have right now, but it requires sessions every two weeks. It’s only available at specialized centers, and it’s reserved for people with extremely high levels who have already had cardiovascular events despite other treatments. Then there’s the injectable PCSK9 inhibitors, evolocumab and alirocumab. These do reduce LP little a as a secondary effect by about 20 to 25%. They were not designed for this, but it is a real effect. The really exciting development and the one I think is genuinely gonna make the most impact is a class of drugs called siRNA therapies. These work by going directly to the liver and essentially turning down the expression of the LPA gene. Early trials have shown LP little a reductions of 70 to 90% with dosing intervals every three to six months. The major outcomes trials are underway, so I’m watching this space very closely.

[26:39 –> 27:14] Dr. Ravi Kumar: But here’s my honest take. The pipeline is exciting. And when we have outcomes trials that show a survival benefit from specific LP reductions, that will be a genuine game changer for certain people. But waiting for that drug is not a strategy. The lifestyle levers that we talked about are available right now. They have no side effects, and they address the root cause of how LP little a causes harm. And that is where it’s wise to put most of your energy. Okay. So let me bring this all together. Lipoprotein little a is one of the most fascinating stories in cardiovascular medicine. It’s billed as a disease gene, but it’s actually a survival gene that has been mismatched to modern civilization. Your ancestors with high LP little a survived childbirth hemorrhage, battle wounds, and infections that killed people with lower levels of LP little a. That’s why it’s still here, and that’s why it’s in you.

[27:14 –> 28:10] Dr. Ravi Kumar: The question for you today is not how to lower your LP little a level, because right now, you really can’t, at least not meaningfully. The question is how to live in a way that never gives your LP what it needs to cause harm. So how do you do that? Well, we talked about it, but let me recap. First, reduce your endothelial injury rate by controlling blood pressure, optimizing metabolic health, and not smoking. And two, eliminate oxidizable fuels in large quantities from your diet by getting seed oils out and cooking with only stable, healthy fats. And also stay active, not because exercise changes your LP little a number, but because a healthy vascular environment is more resilient. So if your LP levels are high, like mine, you’re not broken. You’re not on an inevitable path to heart disease. You have a genetic trait that is biologically fascinating, that conferred real advantages to your ancestors, and that is entirely manageable with the right lifestyle framework. High LP little a was a superpower in the ancestral environment.

[28:10 –> 28:35] Dr. Ravi Kumar: And today, you just need to build the environment for your biology to function the way it was designed. Okay. So that’s the pod, folks. I hope you enjoyed it. And if you found this useful, I’d really invite you to share it with someone in your life who’s been told they have high lipoprotein levels, and they don’t know what to do with that information. Information and knowledge are power, and if you can give that gift to someone, it will empower them to live better. And if you have questions, send me an email or leave a comment. And please rate and review the podcast on Apple Podcasts if you can. I really appreciate it.

[28:35 –> 28:39] Dr. Ravi Kumar: So until next time, stay curious, stay skeptical, and stay healthy. Cheers.